Tandem Diabetes Care is a medical device company with an innovative, user-centric and integrated approach to the design, development, and commercialization of products for people with diabetes who use insulin. The Company manufactures and sells a family of insulin pump products, which includes the t:slim X2™ Insulin Pump, the next-generation color touchscreen pump, the t:flex® Insulin Pump, the first pump designed for people with greater insulin requirements, and the t:slim G4™ Insulin Pump, the first CGM-enabled pump with touch-screen simplicity.

Type
Public
HQ
San Diego, US
Founded
2006
Size (employees)
591 (est)
Tandem Diabetes Care was founded in 2006 and is headquartered in San Diego, US
Report incorrect company information

Key People/Management at Tandem Diabetes Care

Kim D. Blickenstaff

Kim D. Blickenstaff

President , CEO & Board Of Director
John Cajigas

John Cajigas

CFO
Jim Leal

Jim Leal

VP, Operations
Bob Anacone

Bob Anacone

EVP and Chief Commercial Officer
Susan Morrison

Susan Morrison

VP, HR, Corporate & Investor Relations

Tandem Diabetes Care Office Locations

Tandem Diabetes Care has an office in San Diego
San Diego, US (HQ)
11045 Roselle St
Show all (1)
Report incorrect company information

Tandem Diabetes Care Financials and Metrics

Tandem Diabetes Care Financials

Tandem Diabetes Care's revenue was reported to be $107.60 m in FY, 2017
USD

Revenue (FY, 2017)

107.6 m

Gross profit (FY, 2017)

44.1 m

Gross profit margin (FY, 2017), %

41%

Net income (FY, 2017)

(73 m)

EBIT (FY, 2017)

(62.9 m)

Market capitalization (25-Apr-2018)

41.2 m

Cash (31-Dec-2017)

13.7 m
Tandem Diabetes Care's current market capitalization is $41.2 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

49.7 m72.9 m84.2 m107.6 m

Revenue growth, %

47%16%

Cost of goods sold

34.5 m46.3 m60.7 m63.5 m

Gross profit

15.2 m26.6 m23.6 m44.1 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

15.7 m15.7 m20.1 m23 m12.3 m19 m21.3 m27 m

Cost of goods sold

10.9 m10.2 m13.1 m14.8 m13.9 m12.2 m13.3 m15.1 m

Gross profit

4.8 m5.5 m6.9 m8.2 m(1.6 m)6.8 m8 m11.9 m

Gross profit Margin, %

31%35%35%36%(13%)36%38%44%
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

31.2 m43.1 m44.7 m13.7 m

Accounts Receivable

7.7 m14.1 m11.2 m20.8 m

Inventories

11.9 m17.5 m21.2 m27 m

Current Assets

90.8 m107 m92.1 m64.2 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(79.5 m)(72.4 m)(83.4 m)(73 m)

Depreciation and Amortization

4.4 m4.8 m5.5 m6.9 m

Inventories

(1.8 m)(6.1 m)(6.9 m)

Accounts Payable

(1.2 m)3.4 m3.2 m(2 m)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(19.5 m)(19.6 m)(20.5 m)(18.3 m)(29.8 m)(23.8 m)

Inventories

10.2 m11.1 m11.9 m14.7 m17.6 m20.2 m21.7 m22.9 m

Accounts Payable

2.1 m2.5 m3 m4.1 m4 m4 m6 m6.8 m5.6 m4.9 m6.6 m7.6 m
USDY, 2017

Revenue/Employee

182.1 k

Financial Leverage

-3.3 x
Show all financial metrics

Tandem Diabetes Care Operating Metrics

Tandem Diabetes Care's Devices Sold was reported to be 50 k in FY, 2016.
FY, 2016

Devices Sold

50 k

Patents Issued

50

Patents Pending

46

Trademarks

23
Show all operating metrics
Report incorrect company information